(Q43292200)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680526%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

title

Effective testosterone suppression for prostate cancer: is there a best castration therapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680526%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

1 reference

1 reference

Leonard G Gomella

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2725306&resulttype=core&format=json

14 May 2020

publication date

1 January 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19680526%20AND%20SRC:MED&resulttype=core&format=json

5 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2725306&resulttype=core&format=json

14 May 2020

volume

11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2725306&resulttype=core&format=json

14 May 2020

issue

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2725306&resulttype=core&format=json

14 May 2020

page(s)

52-60

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2725306&resulttype=core&format=json

Immediate versus deferred treatment for advanced prostatic cancer: initial results of the Medical Research Council trial. The Medical Research Council Prostate Cancer Working Party Investigators Group

14 May 2020

cites work

1 reference

12 December 2020

Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer Trialists' Collaborative Group

1 reference

12 December 2020

Differential impact of age, sex steroid hormones, and obesity on basal versus pulsatile growth hormone secretion in men as assessed in an ultrasensitive chemiluminescence assay

1 reference

12 December 2020

The time for serum testosterone to reach castrate level after bilateral orchiectomy or oral estrogen in the management of metastatic prostatic cancer

1 reference

12 December 2020

Effect of orchidectomy on serum concentrations of testosterone and dihydrotestosterone in patients with prostatic cancer

1 reference

12 December 2020

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

12 December 2020

LH-RH Agonists and Antagonists

1 reference

12 December 2020

Proceedings: The Veterans Administration Cooperative Urological Research Group's studies of cancer of the prostate

1 reference

12 December 2020

Estrogen dosage and suppression of testosterone levels in patients with prostatic carcinoma

1 reference

12 December 2020

LH-releasing activity of potent LH-RH analogs in vitro

1 reference

12 December 2020

Comparative efficacy of triptorelin pamoate and leuprolide acetate in men with advanced prostate cancer

1 reference

12 December 2020

3-Month Formulation of Goserelin Acetate (‘Zoladex’ 10.8-mg Depot) in Advanced Prostate Cancer: Results from an Italian, Open, Multicenter Trial

1 reference

12 December 2020

Serum testosterone suppression and potential for agonistic stimulation during chronic treatment with monthly and 3-month depot formulations of leuprolide acetate for advanced prostate cancer

1 reference

12 December 2020

Studies on prostatic cancer. I. The effect of castration, of estrogen and of androgen injection on serum phosphatases in metastatic carcinoma of the prostate. 1941.

1 reference

12 December 2020

Diethylstilbesterol revisited: androgen deprivation, osteoporosis and prostate cancer

1 reference

12 December 2020

Is the flare phenomenon clinically significant?

1 reference

12 December 2020

The effects of androgen deprivation on the prostate gland: cell death mediated by vascular regression

1 reference

12 December 2020

Complications of androgen deprivation therapy in prostate cancer

1 reference

12 December 2020

Current prostate cancer treatments: effect on quality of life

1 reference

12 December 2020

The relationship of body mass index and serum testosterone with disease outcomes in men with castration-resistant metastatic prostate cancer.

1 reference

12 December 2020

Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism.

1 reference

12 December 2020

Will GnRH antagonists improve prostate cancer treatment?

1 reference

12 December 2020

The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer

1 reference

12 December 2020

Combined androgen blockade in advanced prostate cancer: looking back to move forward

1 reference

12 December 2020

Redefining clinically significant castration levels in patients with prostate cancer receiving continuous androgen deprivation therapy.

1 reference

12 December 2020

Obesity and treatment of prostate cancer: what is the right dose of Lupron Depot?

1 reference

12 December 2020

Evolving issues in male hypogonadism: evaluation, management, and related comorbidities.

1 reference

12 December 2020

LHRH agonists in prostate cancer: frequency of treatment, serum testosterone measurement and castrate level: consensus opinion from a roundtable discussion

1 reference

12 December 2020

Initial hormonal management of androgen-sensitive metastatic, recurrent, or progressive prostate cancer: 2006 update of an American Society of Clinical Oncology practice guideline

1 reference

12 December 2020

The current status of intermittent androgen deprivation (IAD) therapy for prostate cancer: putting IAD under the spotlight

1 reference

12 December 2020

Obesity and sex steroids during gonadotropin-releasing hormone agonist treatment for prostate cancer

1 reference

12 December 2020

Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162).

1 reference

12 December 2020

Immediate versus deferred androgen deprivation treatment in patients with node-positive prostate cancer after radical prostatectomy and pelvic lymphadenectomy

1 reference

12 December 2020

Failure to achieve castration levels in patients using leuprolide acetate in locally advanced prostate cancer

1 reference

12 December 2020

Androgen deprivation therapy for prostate cancer

1 reference

12 December 2020

1 reference

12 December 2020

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

12 December 2020

An evaluation of pharmacokinetics and pharmacodynamics of leuprorelin acetate 3M-depot in patients with advanced and metastatic carcinoma of the prostate

1 reference

12 December 2020

Reassessment of the definition of castrate levels of testosterone: implications for clinical decision making

1 reference

12 December 2020

Failure to achieve castrate levels of testosterone during luteinizing hormone releasing hormone agonist therapy: the case for monitoring serum testosterone and a treatment decision algorithm.

1 reference

12 December 2020

Improved Survival in Patients with Locally Advanced Prostate Cancer Treated with Radiotherapy and Goserelin

1 reference

12 December 2020

Identifiers

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=PMCID:PMC2725306&resulttype=core&format=json

14 May 2020

1 reference